Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic

Purpose Patients with age-related macular degeneration (ARMD) are required to follow a treatment protocol that requires regular follow-ups. The COVID-19 pandemic has created an additional burden for patients with ARMD under treatment with anti-vascular endothelial growth factor (anti-VEGF) injection...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International ophthalmology 2022-08, Vol.42 (8), p.2493-2499
Hauptverfasser: Mylona, Ioanna, Papadopoulou, Kalliopi, Roumelis, Serafeim, Floros, Georgios D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2499
container_issue 8
container_start_page 2493
container_title International ophthalmology
container_volume 42
creator Mylona, Ioanna
Papadopoulou, Kalliopi
Roumelis, Serafeim
Floros, Georgios D.
description Purpose Patients with age-related macular degeneration (ARMD) are required to follow a treatment protocol that requires regular follow-ups. The COVID-19 pandemic has created an additional burden for patients with ARMD under treatment with anti-vascular endothelial growth factor (anti-VEGF) injections, since patients face a congestion of the health system and closing of the outpatient services. This study examines the impact of the uncertainty regarding patients’ treatment on their sense of well-being. Methods This is a longitudinal cohort study of eighty patients who were followed during the year following the outbreak of the COVID pandemic. Patients reported their sense of well-being with the WHO-5 questionnaire and their perception and fears for the impact of the pandemic on their ongoing ARMD treatment. Results There was a significant drop in mental well-being during the pandemic that paralleled the self-reported impact of the pandemic on ARMD treatment. Patients who reported a higher impact of COVID-19 on their treatment had experienced a higher drop in mental wellbeing compared to those who hadn’t, with female gender being an additional risk factor. Objective measurements of visual acuity did not factor in the drop of sense of well-being. Conclusions The high initial level of uncertainty regarding ARMD patients’ long-term course was further exacerbated when exposed to additional uncertainties during the pandemic regarding their standard of care. Planning ahead for continuation of services and close contact with patients during similar health emergencies is of paramount importance.
doi_str_mv 10.1007/s10792-022-02296-4
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8972774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646717453</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-2f70b00a09df089f9b4663fe5b98ee23b2f42993be45f4b1e605aa910c6cdf0c3</originalsourceid><addsrcrecordid>eNp9kUuPFCEUhYnROA_9Ay4MiRs3KK-CYmMy6Z5XMmYSo7MlFA3TdLqgBMqJ_156ehxHFy4IBL5zuPceAN4Q_IFgLD8WgqWiCNP7pQTiz8Ah6SRDVDD8_Mn5AByVssEYK6nES3DAOiZoT8gh2CxzmmCI8M5tt2hwId7C5OHJl89LOJkaXKwFznHlMqzZmTq2C3gX6hqaWAO6OT0_a-qNszWkWOBqzjuHunZwcX1zuURENZsmH4N9BV54sy3u9cN-DL6dnX5dXKCr6_PLxckVslzyiqiXeMDYYLXyuFdeDVwI5l03qN45ygbqOVWKDY53ng_ECdwZowi2wjaFZcfg0953mofRrWyrOJutnnIYTf6pkwn675cY1vo2_dC9klRK3gzePxjk9H12peoxFNvmY6JLc9FUcCGJ5B1r6Lt_0E2ac2ztNUpxgmnf00bRPWVzKiU7_1gMwXoXpd5HqVuM-j5Kvavi7dM2HiW_s2sA2wNl2g3d5T9__8f2F-P8qXU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2694102882</pqid></control><display><type>article</type><title>Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic</title><source>SpringerNature Journals</source><creator>Mylona, Ioanna ; Papadopoulou, Kalliopi ; Roumelis, Serafeim ; Floros, Georgios D.</creator><creatorcontrib>Mylona, Ioanna ; Papadopoulou, Kalliopi ; Roumelis, Serafeim ; Floros, Georgios D.</creatorcontrib><description>Purpose Patients with age-related macular degeneration (ARMD) are required to follow a treatment protocol that requires regular follow-ups. The COVID-19 pandemic has created an additional burden for patients with ARMD under treatment with anti-vascular endothelial growth factor (anti-VEGF) injections, since patients face a congestion of the health system and closing of the outpatient services. This study examines the impact of the uncertainty regarding patients’ treatment on their sense of well-being. Methods This is a longitudinal cohort study of eighty patients who were followed during the year following the outbreak of the COVID pandemic. Patients reported their sense of well-being with the WHO-5 questionnaire and their perception and fears for the impact of the pandemic on their ongoing ARMD treatment. Results There was a significant drop in mental well-being during the pandemic that paralleled the self-reported impact of the pandemic on ARMD treatment. Patients who reported a higher impact of COVID-19 on their treatment had experienced a higher drop in mental wellbeing compared to those who hadn’t, with female gender being an additional risk factor. Objective measurements of visual acuity did not factor in the drop of sense of well-being. Conclusions The high initial level of uncertainty regarding ARMD patients’ long-term course was further exacerbated when exposed to additional uncertainties during the pandemic regarding their standard of care. Planning ahead for continuation of services and close contact with patients during similar health emergencies is of paramount importance.</description><identifier>ISSN: 1573-2630</identifier><identifier>ISSN: 0165-5701</identifier><identifier>EISSN: 1573-2630</identifier><identifier>DOI: 10.1007/s10792-022-02296-4</identifier><identifier>PMID: 35362811</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acuity ; Age ; Age related diseases ; Coronaviruses ; COVID-19 ; Eye diseases ; Growth factors ; Macular degeneration ; Medicine ; Medicine &amp; Public Health ; Ophthalmology ; Original Paper ; Pandemics ; Patients ; Risk analysis ; Risk factors ; Uncertainty ; Vascular endothelial growth factor ; Visual acuity ; Visual aspects ; Well being</subject><ispartof>International ophthalmology, 2022-08, Vol.42 (8), p.2493-2499</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature B.V.</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-2f70b00a09df089f9b4663fe5b98ee23b2f42993be45f4b1e605aa910c6cdf0c3</citedby><cites>FETCH-LOGICAL-c474t-2f70b00a09df089f9b4663fe5b98ee23b2f42993be45f4b1e605aa910c6cdf0c3</cites><orcidid>0000-0002-1032-3730</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10792-022-02296-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10792-022-02296-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35362811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mylona, Ioanna</creatorcontrib><creatorcontrib>Papadopoulou, Kalliopi</creatorcontrib><creatorcontrib>Roumelis, Serafeim</creatorcontrib><creatorcontrib>Floros, Georgios D.</creatorcontrib><title>Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic</title><title>International ophthalmology</title><addtitle>Int Ophthalmol</addtitle><addtitle>Int Ophthalmol</addtitle><description>Purpose Patients with age-related macular degeneration (ARMD) are required to follow a treatment protocol that requires regular follow-ups. The COVID-19 pandemic has created an additional burden for patients with ARMD under treatment with anti-vascular endothelial growth factor (anti-VEGF) injections, since patients face a congestion of the health system and closing of the outpatient services. This study examines the impact of the uncertainty regarding patients’ treatment on their sense of well-being. Methods This is a longitudinal cohort study of eighty patients who were followed during the year following the outbreak of the COVID pandemic. Patients reported their sense of well-being with the WHO-5 questionnaire and their perception and fears for the impact of the pandemic on their ongoing ARMD treatment. Results There was a significant drop in mental well-being during the pandemic that paralleled the self-reported impact of the pandemic on ARMD treatment. Patients who reported a higher impact of COVID-19 on their treatment had experienced a higher drop in mental wellbeing compared to those who hadn’t, with female gender being an additional risk factor. Objective measurements of visual acuity did not factor in the drop of sense of well-being. Conclusions The high initial level of uncertainty regarding ARMD patients’ long-term course was further exacerbated when exposed to additional uncertainties during the pandemic regarding their standard of care. Planning ahead for continuation of services and close contact with patients during similar health emergencies is of paramount importance.</description><subject>Acuity</subject><subject>Age</subject><subject>Age related diseases</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Eye diseases</subject><subject>Growth factors</subject><subject>Macular degeneration</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Ophthalmology</subject><subject>Original Paper</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Uncertainty</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><subject>Visual aspects</subject><subject>Well being</subject><issn>1573-2630</issn><issn>0165-5701</issn><issn>1573-2630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUuPFCEUhYnROA_9Ay4MiRs3KK-CYmMy6Z5XMmYSo7MlFA3TdLqgBMqJ_156ehxHFy4IBL5zuPceAN4Q_IFgLD8WgqWiCNP7pQTiz8Ah6SRDVDD8_Mn5AByVssEYK6nES3DAOiZoT8gh2CxzmmCI8M5tt2hwId7C5OHJl89LOJkaXKwFznHlMqzZmTq2C3gX6hqaWAO6OT0_a-qNszWkWOBqzjuHunZwcX1zuURENZsmH4N9BV54sy3u9cN-DL6dnX5dXKCr6_PLxckVslzyiqiXeMDYYLXyuFdeDVwI5l03qN45ygbqOVWKDY53ng_ECdwZowi2wjaFZcfg0953mofRrWyrOJutnnIYTf6pkwn675cY1vo2_dC9klRK3gzePxjk9H12peoxFNvmY6JLc9FUcCGJ5B1r6Lt_0E2ac2ztNUpxgmnf00bRPWVzKiU7_1gMwXoXpd5HqVuM-j5Kvavi7dM2HiW_s2sA2wNl2g3d5T9__8f2F-P8qXU</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Mylona, Ioanna</creator><creator>Papadopoulou, Kalliopi</creator><creator>Roumelis, Serafeim</creator><creator>Floros, Georgios D.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1032-3730</orcidid></search><sort><creationdate>20220801</creationdate><title>Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic</title><author>Mylona, Ioanna ; Papadopoulou, Kalliopi ; Roumelis, Serafeim ; Floros, Georgios D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-2f70b00a09df089f9b4663fe5b98ee23b2f42993be45f4b1e605aa910c6cdf0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acuity</topic><topic>Age</topic><topic>Age related diseases</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Eye diseases</topic><topic>Growth factors</topic><topic>Macular degeneration</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Ophthalmology</topic><topic>Original Paper</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Uncertainty</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><topic>Visual aspects</topic><topic>Well being</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mylona, Ioanna</creatorcontrib><creatorcontrib>Papadopoulou, Kalliopi</creatorcontrib><creatorcontrib>Roumelis, Serafeim</creatorcontrib><creatorcontrib>Floros, Georgios D.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mylona, Ioanna</au><au>Papadopoulou, Kalliopi</au><au>Roumelis, Serafeim</au><au>Floros, Georgios D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic</atitle><jtitle>International ophthalmology</jtitle><stitle>Int Ophthalmol</stitle><addtitle>Int Ophthalmol</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>42</volume><issue>8</issue><spage>2493</spage><epage>2499</epage><pages>2493-2499</pages><issn>1573-2630</issn><issn>0165-5701</issn><eissn>1573-2630</eissn><abstract>Purpose Patients with age-related macular degeneration (ARMD) are required to follow a treatment protocol that requires regular follow-ups. The COVID-19 pandemic has created an additional burden for patients with ARMD under treatment with anti-vascular endothelial growth factor (anti-VEGF) injections, since patients face a congestion of the health system and closing of the outpatient services. This study examines the impact of the uncertainty regarding patients’ treatment on their sense of well-being. Methods This is a longitudinal cohort study of eighty patients who were followed during the year following the outbreak of the COVID pandemic. Patients reported their sense of well-being with the WHO-5 questionnaire and their perception and fears for the impact of the pandemic on their ongoing ARMD treatment. Results There was a significant drop in mental well-being during the pandemic that paralleled the self-reported impact of the pandemic on ARMD treatment. Patients who reported a higher impact of COVID-19 on their treatment had experienced a higher drop in mental wellbeing compared to those who hadn’t, with female gender being an additional risk factor. Objective measurements of visual acuity did not factor in the drop of sense of well-being. Conclusions The high initial level of uncertainty regarding ARMD patients’ long-term course was further exacerbated when exposed to additional uncertainties during the pandemic regarding their standard of care. Planning ahead for continuation of services and close contact with patients during similar health emergencies is of paramount importance.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>35362811</pmid><doi>10.1007/s10792-022-02296-4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1032-3730</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1573-2630
ispartof International ophthalmology, 2022-08, Vol.42 (8), p.2493-2499
issn 1573-2630
0165-5701
1573-2630
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8972774
source SpringerNature Journals
subjects Acuity
Age
Age related diseases
Coronaviruses
COVID-19
Eye diseases
Growth factors
Macular degeneration
Medicine
Medicine & Public Health
Ophthalmology
Original Paper
Pandemics
Patients
Risk analysis
Risk factors
Uncertainty
Vascular endothelial growth factor
Visual acuity
Visual aspects
Well being
title Drop in well-being of ARMD patients under treatment with anti-VEGF injections during the COVID-19 pandemic
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A40%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drop%20in%20well-being%20of%20ARMD%20patients%20under%20treatment%20with%20anti-VEGF%20injections%20during%20the%20COVID-19%20pandemic&rft.jtitle=International%20ophthalmology&rft.au=Mylona,%20Ioanna&rft.date=2022-08-01&rft.volume=42&rft.issue=8&rft.spage=2493&rft.epage=2499&rft.pages=2493-2499&rft.issn=1573-2630&rft.eissn=1573-2630&rft_id=info:doi/10.1007/s10792-022-02296-4&rft_dat=%3Cproquest_pubme%3E2646717453%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2694102882&rft_id=info:pmid/35362811&rfr_iscdi=true